Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Yttrium Y 90 Resin Microspheres in Collecting Data from Patients with Liver Cancer That Cannot Be Removed by Surgery for the RESIN Liver Tumor Study

This research trial studies Yttrium Y 90 resin microspheres in collecting data from patients with liver cancer not capable of being removed by surgery (unresectable) for the radiation-emitting SIR-spheres in non-resectable (RESIN) liver tumor study. The information generated will help doctors better understand treatment patterns involving Y90 therapy, gain additional insights in the long-term outcomes for patients, as well as guide future research for using Y90 therapy, especially for those conditions where data is currently very limited or lacking.
Not Available
Not Available
Brown, Daniel
Advocate Christ Medical Center, Albany Medical Center, Baptist Health South Florida, California Pacific Medical Center-Pacific Campus, Carolinas Medical Center, Case Western Reserve University, Cedars-Sinai Medical Center, Christiana Care Health Services, Columbia University Medical Center, Dana-Farber Cancer Institute, Emory University, Georgetown University, Houston Methodist Hospital, Huntsman Cancer Institute/University of Utah, Icahn School of Medicine at Mount Sinai, Lenox Hill Hospital, Methodist Dallas Medical Center, New York University, Ochsner Medical Center, Oregon Health Sciences University, Penn State Health Saint Joseph Medical Center, Piedmont Hospital, Providence Sacred Heart Med Center and Children's Hosp, Radiology Imaging Associates, Ronald Reagan UCLA Medical Center, Roswell Park Cancer Institute, Saint Louis University Hospital, Sanford USD Medical Center - Sioux Falls, Sarasota Memorial Hospital, Southeastern Regional Medical Center CTCA, Spartanburg Regional Medical Center, Stanford University, Tampa General Hospital, Texas Liver Institute, The Cleveland Clinic, UT Health Science Center at San Antonio, Univ of Pennsylvania Cancer Center, University California, Irvine, University Hospitals of Cleveland, University of Alabama/Birmingham, University of Arizona Health Sciences, University of Arkansas for Medical Sciences, University of California, San Francisco, University of Colorado, Denver, University of Kansas Cancer Center, University of Maryland, Baltimore, University of Miami Miller School of Medicine, University of Minnesota, Vanderbilt University, Wake Forest University Health Sciences, Washington University Ctr for Clinical Studies
Radiation-Emitting SIR-Spheres Non-resectable (RESIN) Liver Tumor Patient Study


18 Years
Inclusion Criteria:

Receiving SIR-spheres therapy to the liver for the first time

Provision of written informed consent

Exclusion Criteria:

Prior completion of Y90 therapy to the liver (SIR-spheres, TheraSpheres, or any other liver-targeted therapy involving the use of radiation-emitting spheres) * Patients who have received Y90 treatment in the past and who are returning for another Y90 treatment are ineligible, even if new areas are being targeted * Exclusion criteria caveats: ** Patients who have not completed their first-ever course of SIR-spheres therapy are considered eligible for the study, as long as they are consented before the completion of their final treatment session ** Patients who have undergone peptide receptor Y-90 radionuclide therapy (PRRT) are considered eligible for the study

Need for surrogate consent; patients unable to consent on their own behalves are not eligible for this study

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: